CureVac Shareholders Face Pivotal Decision on BioNTech Takeover Bid

The acquisition drama surrounding German biopharmaceutical firm CureVac approaches its climax as investors prepare for a landmark shareholder vote. With regulatory hurdles cleared and critical deadlines looming, stakeholders must determine whether to accept BioNTech’s substantial share-exchange proposal.

German financial authorities have removed the final obstacle to the takeover process. The Federal Financial Supervisory Authority (BaFin) approved a crucial amendment to the exchange offer on November 11, paving the way for CureVac’s extraordinary general meeting scheduled for November 25. This gathering will represent a defining moment for the company’s investors.

Shareholders who previously committed to the arrangement maintain withdrawal rights until November 14, introducing a final opportunity for Read more...